New insider activity at Amneal Pharmaceuticals ( (AMRX) ) has taken place on March 18, 2025.
Significant shareholder Tushar Bhikhubhai Patel has made a notable move by selling 5,000,000 shares of Amneal Pharmaceuticals stock, amounting to a transaction worth $41,750,000.
Recent Updates on AMRX stock
Amneal Pharmaceuticals has seen a positive shift in its stock outlook following the announcement that the FDA has accepted its Biologics Licensing Application for two denosumab biosimilars. This development, alongside strong financial results for 2024, has led Barclays to raise its price target for Amneal. The company’s Q4 performance exceeded expectations, with a notable 18% increase in net revenue driven by new product launches and significant growth across all business segments. Amneal’s strategic initiatives, such as entering the weight loss market and successful product launches like Crexent, have bolstered investor confidence. Despite challenges like the impending Rytary loss of exclusivity and slow Naloxone market progress, Amneal’s deleveraging success and credit rating upgrades reflect its strong financial health. The company projects continued growth in 2025, with expected net revenue between $3.0 billion and $3.1 billion, and plans to expand its product offerings in high-growth areas.
More about Amneal Pharmaceuticals
YTD Price Performance: 12.76%
Average Trading Volume: 1,432,364
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.71B